Welcome to the e-CCO Library!

P619 Efficacy of zinc acetate hydrate administration for zinc deficiency in patients with inflammatory bowel disease: a multi-centre retrospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Sakurai1, T. Katsurada1, S. Otagiri1, K. Yamanashi1, K. Nagashima1, R. Onishi1, H. Nishimura2, T. Ito2, S. Furukawa2, A. Maemoto2, N. Sakamoto1

Created: Thursday, 30 January 2020, 10:12 AM
P619: Incidence of collagenous colitis in NHS Lothian: a population-based study
Year: 2021
Source: ECCO'21 Virtual
Authors: Grant, R.(1);Brindle, W.M.(1);Robertson, A.J.(2);Robertson, A.R.(1);Jones, G.R.(1);Kirkwood, K.J.(3);Fineron, P.W.(3);Arnott, I.D.R.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P619: Inflammatory bowel disease meets fertility: a physicians and patients survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vieujean, S.(1)*;De Vos, M.(2);D'Amico, F.(3,4);Paridaens, K.(5);Daftary, G.(6);Peyrin-Biroulet, L.(7,8);Danese, S.(3);
Created: Friday, 14 July 2023, 11:05 AM
P619: Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. T. Rubin1, S. Travis2, B. P. Abraham3, C. Su4, N. Lawendy4, H. Fan4, D. A. Woodworth4, A. J. Thorpe4, C. I. Nduaka4, D. Quirk4, W. Reinisch*5

Created: Friday, 22 February 2019, 9:41 AM
P619: Patterns of Anti-TNF Prescribing & Therapy Outcome in a Large Multicentre Cohort of Inflammatory Bowel Disease Patients
Year: 2022
Source: ECCO'22
Authors: Doherty, J.(1);Stack, R.(2);O Morain, N.(2);Coe, C.(2);Corcoran, R.(3);Ryan, B.(4);Doherty, G.(2);Mc Namara, D.(5);Kevans, D.(6);
Created: Friday, 11 February 2022, 3:56 PM
P619: Systematic review: Psychosocial factors associated with pain in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Sweeney1*, W. Czuber-Dochan1, R. Moss-Morris2, G. Chumbley3, L. Meade4, C. Norton1

Created: Thursday, 21 February 2019, 9:14 AM
P619: Tofacitinib for the treatment of resistant ulcerative colitis: the University of Chicago experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Weisshof R., Aharoni Golan M., Masching A., Rubin D.T.

Created: Wednesday, 20 February 2019, 10:36 AM
P620 Maintenance of clinical remission with SB5 biosimilar after switch from adalimumab originator: Real-life experience of a tertiary referral centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Dragoni1,2, A. Pieraccini1, S. Bagnoli1, S. Caini3, G. Macrì1, F. Rogai1, S. Milani1,2, A. Galli1,2, M. Milla1

Created: Thursday, 30 January 2020, 10:12 AM
P620: Can ustekinumab trough and antidrug antibody levels post induction predict treatment failure?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mccrossan, M.(1)*;O'Moráin, N.(1,2);Kumar, L.(1,2);Rowan, C.(1);Sheridan, J.(1);Cullen, G.(1,2);Doherty, G.(1,2);Mulcahy, H.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P620: Differences in illness perceptions of Inflammatory Bowel Disease (IBD) between Healthcare Practitioners (HCPs) and patients in a UK tertiary IBD centre.
Year: 2022
Source: ECCO'22
Authors: Duff, A.(1);Dawson, P.(1);Pavilidis, P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P620: Golimumab in ulcerative colitis: A multi-centre real-world experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Kumar1*, J. Slater1, J. Jones1, T. Troth2, G. Baker3, M. Love4, J. Nahal5, D. Rattehalli1

Created: Thursday, 21 February 2019, 9:14 AM
P620: Network meta-analysis of efficacy and safety of different intravenous iron compounds for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Aksan A.*1,2, Işık H.3, Radeke H.H.2,4, Dignass A.2,5, Stein J.2,6

Created: Wednesday, 20 February 2019, 10:36 AM
P620: Pivoting in a pandemic: The impact of COVID-19 on the provision of care for patients with Inflammatory Bowel Disease – A retrospective study
Year: 2021
Source: ECCO'21 Virtual
Authors: Malhi, G.(1);Chambers, J.(1);Minhas, G.(1);Mikail, M.(1);Khanna, R.(2);Wilson, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P620: Stapled end-to-side vs. side-to-side anastomosis after ileocecectomy for Crohn’s disease: a propensity score-matched analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Brandstetter1, M. Gouvea Monteiro de Camargo1, A. Aiello2, L. Stocchi1, J. M. Church1, T. Hull1, I. Lavery1, S. R. Steele1, S. Holubar*1, M. Valente1

Created: Friday, 22 February 2019, 9:41 AM
P621 Physician preferences for biologics (originator vs. biosimilar) for the treatment of ulcerative colitis in France, Germany and the UK
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Huynh1, S. Hass2, B.E. Sands3, M.S. Duh1, H. Sipsma1, M. Cheng1, A. Lax1, A. NAG4

Created: Thursday, 30 January 2020, 10:12 AM
P621: Combination treatment of biologics with immunomodulator increases risk of infection after discharge in biologics naive steroid refractory acute severe ulcerative colitis patient: A KASID multicenter study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kim, S.J.(1)*;Lee, J.(1);Kim, D.H.(2);Park, S.H.(3);Kim, E.S.(4);Kim, K.O.(5);Lee, Y.J.(6);Song, E.M.(7);Kim, D.S.(8);
Created: Friday, 14 July 2023, 11:05 AM
P621: Efficacy and safety of golimumab in ulcerative colitis. Preliminary data from a multicenter Italian study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bossa F.*1, Valvano M.R.1, Costantino G.2, Vinci E.3, Rispo A.4, Mendolaro M.5, Patturelli M.6, Shaini E.7, Mazzuoli S.8, RIcciardelli C.9, Tursi A.10, Lauria A.11, Paese P.12, Azzarone A.13, Sebkova L.14, Pranzo G.15, Fries W.2, Castiglione F.4, Cappello M.5, Privitera A.3, Principi B.7, Andriulli A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P621: Faecal calprotectin after the induction of anti-TNF therapy predicts mucosal healing in patients with ulcerative colitis: A prospective single-centre study
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Bertani1*, N. de Bortoli1, L. Ceccarelli2, G. Mumolo2, G. Tapete1, E. Albano1, G. Laino1, G. Di Fluri2, M. Bellini2, A. Ricchiuti2, S. Marchi1, F. Costa2

Created: Thursday, 21 February 2019, 9:14 AM
P621: Lactose intolerance assessed by analysis of genetic polymorphism, breath test and symptoms in patients with inflammatory bowel disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Nardone, O.M.(1);Manfellotto, F.(2);D'Onofrio, C.(1);Rocco, A.(1);Annona, G.(2);Sasso, F.(1);De Luca, P.(2);Imperatore, N.(3);Testa, A.(1);de Sire, R.(1);Biffali, E.(2);Castiglione, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P621: Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Bressler*1, G. Mantzaris2, M. Silverberg3, P. Zezos3, D. Stein4, C. Colby5, T. Lissoos6, C. Lopez6, A. Natsios7, G. Radulescu8, H. Patel9, D. Demuth10, A. Yarur11

Created: Friday, 22 February 2019, 9:41 AM